T Taran

1.1k total citations · 2 hit papers
13 papers, 742 citations indexed

About

T Taran is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, T Taran has authored 13 papers receiving a total of 742 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in T Taran's work include Advanced Breast Cancer Therapies (13 papers), HER2/EGFR in Cancer Research (5 papers) and Cancer Treatment and Pharmacology (4 papers). T Taran is often cited by papers focused on Advanced Breast Cancer Therapies (13 papers), HER2/EGFR in Cancer Research (5 papers) and Cancer Treatment and Pharmacology (4 papers). T Taran collaborates with scholars based in United States, Belgium and Switzerland. T Taran's co-authors include Patrick Neven, José Baselga, Michael Gnant, Kathleen I. Pritchard, Howard A. Burris, Martine Piccart, Shinzaburo Noguchi, Wentao Feng, Hope S. Rugo and Alejandra Perez and has published in prestigious journals such as Cancer Research, Annals of Oncology and Geburtshilfe und Frauenheilkunde.

In The Last Decade

T Taran

11 papers receiving 724 citations

Hit Papers

Everolimus plus exemestane for hormone-receptor-positive,... 2014 2026 2018 2022 2014 2021 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
    2014 407 citations Martine Piccart, Gabriel N. Hortobágyi et al. Annals of Oncology profile →
  2. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
    2021 161 citations Dennis J. Slamon, Patrick Neven et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T Taran United States 6 561 505 248 233 113 13 742
Karen Rodriguez-Lorenc United States 8 655 1.2× 600 1.2× 289 1.2× 84 0.4× 179 1.6× 19 793
Sarah Sammons United States 16 399 0.7× 466 0.9× 168 0.7× 119 0.5× 97 0.9× 92 706
Juan Pablo Zarate United States 11 541 1.0× 462 0.9× 255 1.0× 131 0.6× 148 1.3× 29 678
Aurelio Castrellon United States 12 392 0.7× 429 0.8× 210 0.8× 102 0.4× 125 1.1× 34 655
Georgina Garnica Jaliffe United States 3 1.0k 1.8× 905 1.8× 395 1.6× 98 0.4× 273 2.4× 3 1.1k
Keun-Seok Lee South Korea 4 524 0.9× 475 0.9× 233 0.9× 66 0.3× 144 1.3× 7 623
P. Gómez Pardo Spain 9 367 0.7× 566 1.1× 158 0.6× 91 0.4× 71 0.6× 27 716
Barbara Radecka Poland 12 297 0.5× 448 0.9× 134 0.5× 115 0.5× 77 0.7× 59 639
Pier Vitale Nuzzo United States 16 500 0.9× 389 0.8× 298 1.2× 382 1.6× 26 0.2× 58 943
A. Mori Italy 12 729 1.3× 680 1.3× 259 1.0× 65 0.3× 213 1.9× 30 860

Countries citing papers authored by T Taran

Since Specialization
Citations

This map shows the geographic impact of T Taran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T Taran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T Taran more than expected).

Fields of papers citing papers by T Taran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T Taran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T Taran. The network helps show where T Taran may publish in the future.

Co-authorship network of co-authors of T Taran

This figure shows the co-authorship network connecting the top 25 collaborators of T Taran. A scholar is included among the top collaborators of T Taran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T Taran. T Taran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
André, Fabrice, Faye Su, Nadia Solovieff, et al.. (2023). Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Annals of Oncology. 34(11). 1003–1014. 43 indexed citations
3.
Slamon, Dennis J., Patrick Neven, Stephen Chia, et al.. (2021). Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Annals of Oncology. 32(8). 1015–1024. 161 indexed citations breakdown →
4.
5.
Isaacs, Claudine, Ruth O’Regan, Binghe Xu, et al.. (2016). Abstract P4-13-12: Everolimus plus trastuzumab and vinorelbine for trastuzumab-resistant, taxane-pretreated, HER2+ advanced breast cancer: Overall survival results from BOLERO-3. Cancer Research. 76(4_Supplement). P4–13. 2 indexed citations
6.
Rugo, Hope S., Kathleen I. Pritchard, Michael Gnant, et al.. (2014). Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Annals of Oncology. 25(4). 808–815. 93 indexed citations
7.
Piccart, Martine, Gabriel N. Hortobágyi, Mario Campone, et al.. (2014). Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Annals of Oncology. 25(12). 2357–2362. 407 indexed citations breakdown →
8.
Burris, H.A., Michael Gnant, G. N. Hortobágyi, et al.. (2013). Abstract P2-16-17: Characterization of response to everolimus (EVE) in BOLERO-2: A phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2- advanced breast cancer. Cancer Research. 73(24_Supplement). P2–16. 2 indexed citations
9.
10.
Toi, Masakazu, Norikazu Masuda, Fabrice André, et al.. (2013). Abstract P4-12-19: BOLERO-3: Everolimus plus trastuzumab and vinorelbine in Asian patients with HER2-positive metastatic breast cancer. Cancer Research. 73(24_Supplement). P4–12. 1 indexed citations
11.
Isaacs, Claudine, Mustafa Özgüroğlu, Guy Jérusalem, et al.. (2013). Abstract P4-12-18: BOLERO-3: Quality-of-life maintained in patients with metastatic breast cancer treated with everolimus plus trastuzumab plus vinorelbine. Cancer Research. 73(24_Supplement). P4–12. 1 indexed citations
12.
Gnant, Michael, Shinzaburo Noguchi, Yutaka Ito, et al.. (2012). Safety of Everolimus For Women Over 65 Years of Age With Advanced Breast Cancer: 18-Mo Follow-Up of BOLERO-2. Annals of Oncology. 23. ix126–ix127. 1 indexed citations
13.
Piccart, M., José Baselga, H.A. Burris, et al.. (2012). Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer. Cancer Research. 72(24_Supplement). P6–4. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen Rodriguez-Lorenc Breakdown of academic impact, for papers by Sarah Sammons Breakdown of academic impact, for papers by Juan Pablo Zarate Breakdown of academic impact, for papers by Aurelio Castrellon Breakdown of academic impact, for papers by Georgina Garnica Jaliffe Breakdown of academic impact, for papers by Keun-Seok Lee Breakdown of academic impact, for papers by P. Gómez Pardo Breakdown of academic impact, for papers by Barbara Radecka Breakdown of academic impact, for papers by Pier Vitale Nuzzo Breakdown of academic impact, for papers by A. Mori
Rankless by CCL
2026